common.study.topics.clinical

Testing Experimental Medication

common.study.values.description

“Renal PK Study of LC350189”

This is a Phase 1, open-label, parallel-group, multiple-dose study designed to assess the effect of renal impairment on the PK and PD of LC350189.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - LC350189 200 mg

Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of LC350189 in Subjects With Varying Degrees of Renal Impairment

common.study.values.clinical-trial-id

NCT04066712

participant.views.study.view.id

aQWELd